ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1872

Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-2014

Jeffrey Curtis1, Shanette G. Daigle 2, Setareh A. Williams 3, Richard Weiss 3, Yamei Wang 4 and Tarun Arora 2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, 3Radius Health, Inc, Waltham, 4Radius Health, Inc, Waltham

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: fractures and Medicare, osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M114: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (1872–1877)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Osteoporotic fractures are an important public health burden, and with an increasing aging population, the number of Americans at risk of fractures is projected to increase 33% by 2030. The objective of this study was to evaluate osteoporosis management in Medicare enrollees.

Methods: This study included Medicare fee-for-service (FFS) members with a closed fragility (or osteoporosis-related) fracture between 01/01/2010-12/31/2014. Cohort characteristics were computed yearly for 2010-2014 in order to examine secular trends in osteoporosis management. Inclusion criteria for cohort eligibility was age ≥65 at index date, continuous enrollment in Medicare FFS with medical and pharmacy benefits for ≥1 year before index date. Patients with Paget’s disease or malignancy (except non-melanoma skin cancer) at baseline were excluded.

Results: Of 18,936,386 beneficiaries, 885,676 had fracture(s) and met eligibility criteria. Average age was 80.5(±8.4) years, 90.9% were white, and 93.8% female. Over half of patients in each yearly cohort had a comorbidity or a medication that increased fall risk, with approximately 50% of patients using opioids. Despite increased fall risk, osteoporosis diagnosis, screening, and treatment rates at baseline were low and decreased from 2010-2014: DXA: 25%, 24%, 23%, 22%,16%; diagnosis: 7%, 6%, 6%, 5%, 4%; treatment: 29%, 24%, 20%, 16%, 11%. A trend toward lower OP diagnosis and treatment utilization over time was observed.

Conclusion: These findings suggest continued and perhaps worsening osteoporotic fracture management over time. Opportunities exist to better identify and treat patients who have an increased risk of fracture.


Disclosure: J. Curtis, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, 2, 5, Amgen, 2, 5, Amgen Inc., 2, 5, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, Genentech, 2, 5, Janseen, 5, Janssen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Myriad, 2, 5, Patient Centered Outcomes Research Insitute (PCORI), 2, Pfizer, 2, 5, Radius Health, Inc., 9, Regeneron, 2, 5, Roche, 2, 3, 5, Roche/Genentech, 5, UCB, 2, 5; S. Daigle, Radius Health, Inc., 9; S. Williams, Radius Health, Inc., 1, 3; R. Weiss, Radius Health, Inc., 1, 3; Y. Wang, Radius Health, Inc., 1, 3; T. Arora, Radius Health, Inc., 9.

To cite this abstract in AMA style:

Curtis J, Daigle S, Williams S, Weiss R, Wang Y, Arora T. Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-2014 [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/worsening-trends-in-osteoporosis-management-in-the-medicare-population-2010-2014/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/worsening-trends-in-osteoporosis-management-in-the-medicare-population-2010-2014/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology